Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind study of TAK-085 in hypertriglyceridemia
jRCT2080220905Phase 3
- Sponsor
- Takeda
- Start
- Oct 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of doconexent ethyl in hypertriglyceridemia, sponsored by Takeda.
02
Drugs
doconexent ethyl
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on jRCT2080220905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220905.